Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8832657 | 0.94 | POLB (0.46) | LMNAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL20832821 | 0.81 | POLB (0.37) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL5167501 | 0.81 | POLB (0.46) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL18294599 | 0.79 | POLB (0.41) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL18513575 | 0.78 | — | — | |
| SCHEMBL1145497 | 0.78 | — | — | |
| SCHEMBL18413373 | 0.78 | — | — | |
| SCHEMBL5167062 | 0.78 | LMNA (0.47) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL6975491 | 0.78 | TSHR (0.46) | LMNAPOLBALDH1A1NPC1RAB9A | |
| SCHEMBL10951364 | 0.77 | LMNA (0.37) | LMNAPOLBALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | US | claimed |
| WO-2024211274-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2016173425-A1 | A GLUCOPYRANOSYL DERIVATIVE AND PREPARATION METHOD AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-03 | — | — | WO | disclosed |
| EP-2895490-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015043511-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | SELE, CYCS, EPCAM | LMNA 1608/4885POLB 3381/4885ALDH1A1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.